The Patent Trial and Appeal Board (PTAB) seems to have bungled an obviousness analysis (again), and was dinged by the Court of Appeals for the Federal Circuit in E.I. DuPont de Nemours v. Synvina...
On October 26, 2018, the dying plaintiff in the first-of-its-kind case involving Monsanto Co.’s glyphosate product, ROUNDUP®, has accepted a judge’s punitive damages award reduction prior to the...
On September 27, 2018, the Drug Enforcement Agency (DEA) scheduled EPIDIOLEX® as a Schedule V regulated drug under the Controlled Substance Act (CSA). In doing so, the DEA has expressly scheduled a...
An interesting question has been presented to the U.S. Supreme Court when it granted a writ of certiorari on October 26, 2018. That is, is the United States Government, through one of its agencies,...
Since today is Halloween, this blog will commemorate the occasion with a creepy patent. U.S. Patent No. 9,406,092 B2 (‘092) issued on August 2, 2016, for “Targeting items to a user of a social...
On September 7, 2018, the Court of Appeals for the Federal Circuit decided Worlds Inc. v. Bungie, Inc., representing another case in the growing case law of IPRs and specifically, the time-bar...
The Court of Appeals for the Federal Circuit presented an interesting paradox in patent validity challenges, especially when the same parties bring forth essentially the same issues, but have...
On September 10, 2018, the Court of Appeals for the Federal Circuit decided Orexo AB v. Actavis Elizabeth LLC, in what turns out to be a fairly straightforward analysis of an obviousness case under...
U.S. Patent No. 9,675,579 B2 (‘579) issued on June 13, 2017, for “Tetrahydrocannabivarin for use in the treatment of nausea and vomiting.” It was issued to applicant GW Pharma Ltd., of Salisbury,...
Monsanto Co. is fighting back against the $289 million jury verdict for its glyphosate product, ROUNDUP®. On September 19, 2018, Monsanto filed two post-trial motions for relief with the Superior...